Swift Brenna E, Maeda Azusa, Bouchard-Fortier Geneviève
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
Strategic Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Int J Gynecol Cancer. 2023 Apr 3;33(4):585-591. doi: 10.1136/ijgc-2022-004228.
To examine the incidence of perioperative blood transfusion and association with 30 day postoperative outcomes in gynecologic cancer surgery.
The American College of Surgeons National Surgical Quality Improvement Program database was queried to identify all gynecologic oncology cases from 2013 to 2019. Clinical and surgical characteristics and 30 day postoperative complications were retrieved. The primary outcome was 30 day composite morbidity, based on the occurrence of one or more of the 18 adverse events. Secondary outcomes were 30 day mortality, length of stay in hospital, and composite surgical site infection, defined as superficial, deep, or organ space surgical site infection. The χ test and logistic regression analyses were performed to compare the outcomes of patients with and without perioperative blood transfusion.
There were 62 531 surgical gynecologic oncology cases with an overall transfusion incidence of 9.4%. The transfusion incidence was significantly higher at 22.4% with laparotomy compared with 1.7% with minimally invasive surgery (p<0.0001). On multivariable analysis for laparotomy patients, blood transfusion was predictive of composite morbidity (adjusted odds ratio (OR) 1.65, 95% confidence interval (CI) 1.48 to 1.85) and length of stay in hospital ≥5 days (adjusted OR 9.02, 95% CI 8.21 to 9.92). In advanced ovarian cancer patients (n=3890), the incidence of perioperative blood transfusion was 40.8%. On multivariable analysis, perioperative blood transfusion was the most predictive factor for composite morbidity (adjusted OR 1.67, 95% CI 1.35 to 2.07) and length of stay in hospital ≥7 days (adjusted OR 9.75, 95% CI 7.79 to 12.21).
Perioperative blood transfusion is associated with increased composite morbidity and prolonged length of stay in hospital. Preoperative patient optimization and institutional practices should be reviewed to improve the use of blood bank resources and adherence to restrictive blood transfusion protocols.
研究妇科癌症手术围手术期输血的发生率及其与术后30天结局的相关性。
查询美国外科医师学会国家外科质量改进计划数据库,以确定2013年至2019年所有妇科肿瘤病例。收集临床和手术特征以及术后30天的并发症。主要结局是基于18种不良事件中一种或多种的发生情况得出的30天综合发病率。次要结局包括30天死亡率、住院时间以及综合手术部位感染,综合手术部位感染定义为表浅、深部或器官间隙手术部位感染。采用χ检验和逻辑回归分析比较围手术期输血患者与未输血患者的结局。
共有62531例妇科肿瘤手术病例,总体输血发生率为9.4%。开腹手术的输血发生率显著更高,为22.4%,而微创手术的输血发生率为1.7%(p<0.0001)。在对开腹手术患者的多变量分析中,输血可预测综合发病率(调整后的优势比(OR)为1.65,95%置信区间(CI)为1.48至1.85)以及住院时间≥5天(调整后的OR为9.02,95%CI为8.21至9.92)。在晚期卵巢癌患者(n=3890)中,围手术期输血发生率为40.8%。多变量分析显示,围手术期输血是综合发病率(调整后的OR为1.67,95%CI为1.35至2.07)和住院时间≥7天(调整后的OR为9.75,95%CI为7.79至12.21)的最强预测因素。
围手术期输血与综合发病率增加和住院时间延长相关。应审查术前患者优化措施和机构做法,以改善血库资源的使用并遵守限制性输血方案。